{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:51:34Z","timestamp":1774569094152,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.transci.2017.11.010","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T04:18:24Z","timestamp":1510201104000},"page":"804-808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)"],"prefix":"10.1016","volume":"56","author":[{"given":"Emre","family":"Tekg\u00fcnd\u00fcz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Demirkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filiz","family":"Vural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"G\u00f6ker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"\u00d6zdo\u011fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130lhami","family":"Kiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130smet","family":"Aydo\u011fdu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leylag\u00fcl","family":"Kaynar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Ali","family":"Erkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se\u00e7kin","family":"\u00c7a\u011f\u0131rgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevgi","family":"Be\u015f\u0131\u015f\u0131k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simten","family":"Da\u011fda\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebru","family":"Koca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcrhan","family":"Kad\u0131k\u00f6yl\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eren","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fcseyin","family":"Bek\u00f6z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali U\u011fur","family":"Ural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abd\u00fclkadir","family":"Ba\u015ft\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutlu","family":"Arat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Albayrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erman","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alev","family":"Akyol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Zahit","family":"Bolaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oral","family":"Nevruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan Atilla","family":"\u00d6zkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6khan","family":"\u00d6zg\u00fcr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fevzi","family":"Altunta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.transci.2017.11.010_bib0005","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.transci.2017.11.010_bib0010","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"10.1016\/j.transci.2017.11.010_bib0015","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetcs: a consensus of the International myeloma working group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.transci.2017.11.010_bib0020","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2017.11.010_bib0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.transci.2017.11.010_bib0030","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tmrv.2014.08.002","article-title":"Use of laboratory tests to guide initiation of autologous hematopoietic progenitor cell collection by apheresis: results from the multicenter hematopoietic progenitor cell collection by apheresis laboratory trigger survey","volume":"28","author":"Makar","year":"2014","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2017.11.010_bib0035","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","article-title":"Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"20","author":"Duong","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.transci.2017.11.010_bib0040","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilization in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone marrow Transplant"},{"key":"10.1016\/j.transci.2017.11.010_bib0045","series-title":"Current uses and outcomes of hematopoietic stem cell transplantation (HCT): CIBMTR summary slides","author":"D\u2019Souza","year":"2016"},{"key":"10.1016\/j.transci.2017.11.010_bib0050","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/bmt.2016.20","article-title":"Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually","volume":"51","author":"Passweg","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2017.11.010_bib0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.transci.2016.01.013","article-title":"Hematopoietic cell transplant activity of Turkey in 2014: ongoing increase in transplant rates","volume":"54","author":"Tekg\u00fcnd\u00fcz","year":"2016","journal-title":"Transfus Apher Sci"},{"issue":"May","key":"10.1016\/j.transci.2017.11.010_bib0060","article-title":"Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: a systematic review and meta-analysis","volume":"9","author":"Kuan","year":"2017","journal-title":"J ClinApher"},{"issue":"2","key":"10.1016\/j.transci.2017.11.010_bib0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/2040620714565962","article-title":"Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and sibling allogeneic transplant","volume":"6","author":"Uddin","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.transci.2017.11.010_bib0070","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1111\/trf.13233","article-title":"Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"55","author":"Pham","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2017.11.010_bib0075","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.bbmt.2015.05.024","article-title":"Tbo-filgrastim versus filgrastim during mobilization and neutrophil engraftment for autologous stem cell transplantation","volume":"21","author":"Elayan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2017.11.010_bib0080","first-page":"181","article-title":"Mexican biosimilar filgrastim for autologous hematopoietic stem cell mobilization and transplantation","volume":"68","author":"Le\u00f3n-Gonz\u00e1lez","year":"2016","journal-title":"Rev Invest Clin"},{"issue":"3","key":"10.1016\/j.transci.2017.11.010_bib0085","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.transci.2016.03.003","volume":"54","author":"Sivgin","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2017.11.010_bib0090","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/bjh.12345","article-title":"Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment","volume":"162","author":"Publicover","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2017.11.010_bib0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.pharep.2013.09.005","article-title":"A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization","volume":"66","author":"Manko","year":"2014","journal-title":"Pharmacol Rep"},{"issue":"10","key":"10.1016\/j.transci.2017.11.010_bib0100","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jcyt.2015.05.010","article-title":"Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in the de nova multiple myeloma patients","volume":"17","author":"Martino","year":"2015","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.transci.2017.11.010_bib0105","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/trf.14211","article-title":"Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma","volume":"57","author":"Lisenko","year":"2017","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.transci.2017.11.010_bib0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jca.21459","article-title":"Efficacious and safe use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients","volume":"32","author":"Maul","year":"2017","journal-title":"J Clin Apheresis"},{"issue":"3","key":"10.1016\/j.transci.2017.11.010_bib0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.transci.2013.04.007","volume":"48","author":"Sivgin","year":"2013","journal-title":"Transfus Apher Sci"},{"issue":"9","key":"10.1016\/j.transci.2017.11.010_bib0120","doi-asserted-by":"crossref","first-page":"E557","DOI":"10.1002\/ajh.24817","article-title":"A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach","volume":"92","author":"Lanza","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2017.11.010_bib0125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/sj.bmt.1704202","article-title":"A randomized study of 10(g\/kg\/day (single dose) vs 2\u00d75 (g\/kg\/day (split dose) G-CSF as stem cell mobilization regimen in high risk breast cancer patients","volume":"32","author":"Carri\u00f3n","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.transci.2017.11.010_bib0130","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1080\/10428194.2016.1271946","article-title":"Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers","volume":"58","author":"Greil","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transci.2017.11.010_bib0135","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1537-2995.2011.03136.x","article-title":"Effectiveness and cost analysis of \u2018just in time\u2019 salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics","volume":"51","author":"Li","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2017.11.010_bib0140","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jcyt.2015.09.002","article-title":"Hematopoietic progenitor cell mobilization with \u2018just in time\u2019 plerixafor approach is a cost-effective alternative to routine plerixafor use","volume":"17","author":"Veltri","year":"2015","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.transci.2017.11.010_bib0145","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bmt.2015.322","article-title":"Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study","volume":"51","author":"Afifi","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.transci.2017.11.010_bib0150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/trf.13868","article-title":"How to mobilize and collect autologous peripheral blood stem cells?","volume":"57","author":"Yuan","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2017.11.010_bib0155","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bmt.2011.82","article-title":"Proposed definition of \u2018poor mobilizer\u2019 in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group GruppoItaliano Trapianto di Midollo Osseo","volume":"47","author":"Olivieri","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.transci.2017.11.010_bib0160","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1038\/bcj.2014.79","article-title":"Plerixafor is superior chemotherapy for first-line stem cell mobilization, and is effective even in heavily pretreated patients","volume":"4","author":"Clark","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.transci.2017.11.010_bib0165","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2017.11.010_bib0170","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Jun","key":"10.1016\/j.transci.2017.11.010_bib0175","article-title":"UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy","volume":"20","author":"Douglas","year":"2017","journal-title":"J Clin Apher"},{"issue":"4","key":"10.1016\/j.transci.2017.11.010_bib0180","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.3747\/co.23.3137","article-title":"Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario","volume":"23","author":"Kouroukis","year":"2016","journal-title":"Curr Oncol"},{"key":"10.1016\/j.transci.2017.11.010_bib0185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/bmt.2011.73","article-title":"Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia","volume":"47","author":"Mahindra","year":"2012","journal-title":"Bone Marrow Transplant"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050217302677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050217302677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T11:53:38Z","timestamp":1603281218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050217302677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1473050217302677"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2017.11.010","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2017.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}